论文部分内容阅读
目的分析辅助化疗对于CA19-9阳性胃癌患者术后的疗效与预后。方法回顾性分析86例经手术确诊且CA19-9阳性的胃癌患者的临床资料。应用Kaplay-Meier法计算生存率,Log-RanK方法做比较,COX多因素回归分析辅助化疗、肿瘤TNM分期、手术方式、病理类型等多因素对患者预后的影响。结果 (1)5年内死亡病例66例,CA19-9阳性胃癌患者术后化疗后1、3、5年生存率分别为80%、61.82%、30.91%;(2)单因素分析显示肿瘤TNM分期、病理类型、是否化疗与CA19-9阳性胃癌术后患者预后明显相关(均P<0.05);(3)COX回归模型分析显示肿瘤TNM分期、术后化疗是影响CA19-9阳性胃癌术后患者生存的独立因素。结论术后辅助化疗是CA19-9阳性的胃癌生存率的独立影响因素,可延长胃癌术后患者的生存期。
Objective To analyze the effect and prognosis of adjuvant chemotherapy in patients with CA19-9 positive gastric cancer after operation. Methods The clinical data of 86 gastric cancer patients diagnosed by CA19-9 positive surgery were retrospectively analyzed. Kaplan-Meier method was used to calculate the survival rate, Log-RanK method was used to compare, COX multivariate regression analysis of adjuvant chemotherapy, tumor TNM staging, surgical methods, pathological types and other factors on the prognosis of patients. Results (1) Sixty-six deaths within 5 years and one-year, three-year and five-year survival rates of patients with CA19-9 positive gastric cancer after chemotherapy were 80%, 61.82% and 30.91% respectively. (2) Univariate analysis showed that TNM stage (P <0.05); (3) COX regression model analysis showed that the TNM stage of the tumor, postoperative chemotherapy is the impact of postoperative patients with CA19-9-positive gastric cancer Independent factors of survival. Conclusions Postoperative adjuvant chemotherapy is an independent factor for the survival of gastric cancer with positive CA19-9, which can prolong the survival of gastric cancer patients.